Actively Recruiting
A Phase III Study Comparing Torvutatug Samrotecan With or Without Bevacizumab Versus Standard Care as Maintenance Treatment for Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Led by AstraZeneca · Updated on 2026-10-16
600
Participants Needed
124
Research Sites
160 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of torvutatug samrotecan, alone or combined with bevacizumab, compared to standard of care as maintenance treatment for participants with platinum-sensitive relapsed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This Phase III study aims to improve treatment options after relapse with a focus on progression-free survival. Participants are randomly assigned to receive either intravenous torvutatug samrotecan alone or with bevacizumab, or to observation or bevacizumab alone as the comparator. Those assigned to bevacizumab must have previously received at least three cycles of the drug combined with platinum-based chemotherapy during their induction phase. The study includes a 5-year follow-up to assess long-term outcomes. During the trial, participants will undergo regular monitoring including assessments of progression-free survival, overall survival, subsequent therapy use, quality of life, and adverse events graded by standard criteria. Archival tumor samples are collected for analysis, and participants will be followed for up to approximately five years to evaluate treatment effects and safety. The study is conducted by AstraZeneca and includes adult women with confirmed high-grade epithelial ovarian or related cancers.
CONDITIONS
Brief Title
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here